Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
nivolumab programmed cell death protein 1 biotech Successful target TTD , drugbank , DGIDB melanoma[MeSHID:D008545]
Renal Cell Carcinoma[MeSHID:D002292]
Microsatellite Instability[MeSHID:D053842]
Stomach[MeSHID:D013270]
Neoplasm Metastasis[MeSHID:D009362]
Small cell carcinoma of lung[MeSHID:D055752]
Squamous cell carcinoma[MeSHID:D002294]
Mismatch Repair[MeSHID:D053843]
Liver carcinoma[MeSHID:D006528]
Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Adenocarcinoma Of Esophagus[MeSHID:C562730]
Carcinoma
Transitional Cell[MeSHID:D002295]
Hodgkin Disease[MeSHID:D006689]
Disease[MeSHID:D004194]
Coronavirus Infections[MeSHID:D018352]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 2.12 approved inhibitor,antibody
nivolumab programmed cell death protein 1 biotech Successful target TTD , drugbank , DGIDB melanoma[MeSHID:D008545]
Renal Cell Carcinoma[MeSHID:D002292]
Microsatellite Instability[MeSHID:D053842]
Stomach[MeSHID:D013270]
Neoplasm Metastasis[MeSHID:D009362]
Small cell carcinoma of lung[MeSHID:D055752]
Squamous cell carcinoma[MeSHID:D002294]
Mismatch Repair[MeSHID:D053843]
Liver carcinoma[MeSHID:D006528]
Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Adenocarcinoma Of Esophagus[MeSHID:C562730]
Carcinoma
Transitional Cell[MeSHID:D002295]
Hodgkin Disease[MeSHID:D006689]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant mesothelioma[MeSHID:C562839]
Adenocarcinoma[MeSHID:D000230]
Triple Negative Breast Neoplasms[MeSHID:D064726]
Malignant neoplasm of ovary[MeSHID:D010051]
Esophageal Neoplasms[MeSHID:D004938]
Diffuse Large B-Cell Lymphoma[MeSHID:D016403]
Malignant neoplasm of prostate[MeSHID:D011471]
Lymphoma
Follicular[MeSHID:D008224]
Myeloid Leukemia
Chronic[MeSHID:D015464]
Pancreatic carcinoma[MeSHID:C562463]
Pleura[MeSHID:D010994]
Glioblastoma[MeSHID:D005909]
Multiple Myeloma[MeSHID:D009101]
Malignant neoplasm of pancreas[MeSHID:D010190]
Lymphoma[MeSHID:D008223]
Recurrence (disease attribute)[MeSHID:D012008]		 2.12 approved inhibitor,antibody
click here to return to the previous page